These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 16026266

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H, Munusamy S.
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [Abstract] [Full Text] [Related]

  • 23. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
    Huang Q, Liu Q, Ouyang D.
    Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
    Hamada Y, Nakamura J.
    Treat Endocrinol; 2004; 3(4):245-55. PubMed ID: 16026107
    [Abstract] [Full Text] [Related]

  • 26. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
    Kador PF, Wyman M, Oates PJ.
    Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
    [Abstract] [Full Text] [Related]

  • 27. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV, Vyas VK, Goyal RK.
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Role of the polyol pathway in the occurrence of degenerative complications of diabetes].
    Bosquet F, Grimaldi A.
    Presse Med; 1986 May 10; 15(19):879-83. PubMed ID: 3012508
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.
    Park HK, Ahn CW, Lee GT, Kim SJ, Song YD, Lim SK, Kim KR, Huh KB, Lee HC.
    Diabetes Res Clin Pract; 2002 Feb 10; 55(2):151-7. PubMed ID: 11796181
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The pharmacology of aldose reductase inhibitors.
    Kador PF, Robison WG, Kinoshita JH.
    Annu Rev Pharmacol Toxicol; 1985 Feb 10; 25():691-714. PubMed ID: 3923907
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Focus on molecules: aldose reductase.
    Anil Kumar P, Bhanuprakash Reddy G.
    Exp Eye Res; 2007 Dec 10; 85(6):739-40. PubMed ID: 16997295
    [No Abstract] [Full Text] [Related]

  • 38. Relationship between aldose reductase enzyme and the signaling pathway of protein kinase C in an in vitro diabetic retinopathy model.
    Sarikaya M, Yazihan N, Daş Evcimen N.
    Can J Physiol Pharmacol; 2020 Apr 10; 98(4):243-251. PubMed ID: 31743046
    [Abstract] [Full Text] [Related]

  • 39. Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
    Robison WG.
    Adv Exp Med Biol; 1988 Apr 10; 246():365-72. PubMed ID: 3150650
    [Abstract] [Full Text] [Related]

  • 40. Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.
    Masson EA, Boulton AJ.
    Drugs; 1990 Feb 10; 39(2):190-202. PubMed ID: 2109678
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.